CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law

Schall, Brown & Schwartz LLP issued a shareholder-solicitation notice regarding a class action lawsuit against Capricor Therapeutics. The release reminds investors of the September 28, 2026 lead plaintiff deadline for those who purchased shares between December 17, 2025, and July 26, 2026. The complaint alleges Capricor made false statements regarding changes to the statistical analysis plan for its Deramiocel BLA resubmission without FDA agreement. The firm claims the company faced significant risk the FDA would not approve the BLA due to lack of sufficient evidence.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.